Scarica l'app Stockscreener
11.50
2.04%
0.23
Precedente Chiudi:
$11.27
Aprire:
$11.41
Volume 24 ore:
162.49K
Relative Volume:
24.68
Capitalizzazione di mercato:
$237.21M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.39
$11.88
Intervallo di 1 settimana:
$10.72
$11.98
Portata 52W:
$10.72
$11.98
Satellos Bioscience Inc Stock (MSLE) Company Profile
Nome
Satellos Bioscience Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
11.50 | 232.47M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Satellos Bioscience Inc Borsa (MSLE) Ultime notizie
United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq
Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World
Satellos Bioscience Inc. - Baystreet.ca
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - 富途牛牛
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - PharmiWeb.com
Satellos Bioscience to Highlight Muscle-Regeneration Platform at Guggenheim Biotech Summit 2026 - TipRanks
Satellos Bioscience Raises US$57.2 Million in Cross-Border Equity Offering to Advance Muscle Disease Pipeline - TipRanks
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - BioSpace
Latham Advises on Satellos’ US$50 Million Initial US Offering - Legal Desire Media and Insights
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com Canada
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise - pharmiweb.com
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Bioscience raises $57.2 million in public offering - Investing.com
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
(MSCL) Equity Market Report (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
Satellos Bioscience prices $50 million public offering By Investing.com - Investing.com Australia
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - pharmiweb.com
Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq - TipRanks
Satellos Brief: Announcing Pricing of US$50 Million Public Offering in Canada and the United States - marketscreener.com
Satellos Bioscience prices $50 million public offering - Investing.com
Canadian Investment Regulatory Organization Trading HaltMSCL - marketscreener.com
Satellos announces pricing of US$50 million public offering in Canada and the United States - marketscreener.com
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Applicati - pharmiweb.com
Satellos announces launch of public offering in Canada and the United States and filing of application to list on Nasdaq - marketscreener.com
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Plans Cross-Border Share Offering and Nasdaq Listing to Fund Muscle Disease Pipeline - TipRanks
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - marketscreener.com
(MSCL) Advanced Trading Insights (MSCL:CA) - Stock Traders Daily
(MSCL) Strategic Equity Report (MSCL:CA) - Stock Traders Daily
Satellos appoints Antoinette Paone as chief development officer and head of Regulatory Affairs - marketscreener.com
Satellos appoints Antoinette Paone as chief development officer By Investing.com - Investing.com Australia
Satellos Bioscience Taps Antoinette Paone as Chief Development Officer - Contract Pharma
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances - TipRanks
Satellos Biosciences Brief: Appointing Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs - marketscreener.com
Satellos Bioscience Welcomes New Chief Development Officer - GuruFocus
(MSCL) Technical Pivots with Risk Controls (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Brief: Announcing Share Consolidation in Connection with Proposed Nasdaq Listing - marketscreener.com
Satellos Bioscience Consolidates Shares in Push for Nasdaq Listing - 富途牛牛
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Data (MSCL:CA) - Stock Traders Daily
(MSCL) Stock Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy - BioSpace
Satellos (OTCQB: MSCLF) cleared to start SAT-3247 Phase 2 DMD trial in 51 children - Stock Titan
Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’ - Citeline News & Insights
Satellos to Participate in December Investor Conferences - Business Wire
Satellos Bioscience Inc Azioni (MSLE) Dati Finanziari
Non sono disponibili dati finanziari per Satellos Bioscience Inc (MSLE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):